Chinese Novel Drug Developer Hinova Pharma Nets $40M In Series B Round

Login to View

Hinova Pharma, a novel drug developer based in southwestern China’s Chengdu city, announced on Monday the completion of a US$40 million series B round of financing led by healthcare-focused private equity fund Hermed Capital and Chinese listed pharmaceutical firm Fosun Pharma.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in